Abstract
Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Recent Patents on Anti-Cancer Drug Discovery
Title:Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Volume: 8 Issue: 2
Author(s): Riccardo Petrelli, Patrizia Vita, Ilaria Torquati, Krzysztof Felczak, Daniel J. Wilson, Palmarisa Franchetti and Loredana Cappellacci
Affiliation:
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Abstract: Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Export Options
About this article
Cite this article as:
Petrelli Riccardo, Vita Patrizia, Torquati Ilaria, Felczak Krzysztof, J. Wilson Daniel, Franchetti Palmarisa and Cappellacci Loredana, Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020001
DOI https://dx.doi.org/10.2174/1574892811308020001 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Self-Assembly of DNA and Cell-Adhesive Proteins onto pH-Sensitive Inorganic Crystals for Precise and Efficient Transgene Delivery
Current Pharmaceutical Design Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Exposure and Genotoxicity Assessment Methodologies - The Case of Formaldehyde Occupational Exposure
Current Analytical Chemistry Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Modulation of Ornithine Decarboxylase Activity by Phenolics Based Structurally Related Compounds Synthesized on Steroidal and Non-Steroidal Skeleton and their Radical Scavenging Action
Current Bioactive Compounds Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics